10-Q · May 7, 2026
Amylyx Pharmaceuticals achieved a Q1 2026 net loss of $41.3 million, reflecting a negative EPS of -$0.37, beating street expectations of -$0.34. Significant R&D expenditures were noted at $27.6 million, driven primarily…
AMLX earnings analysis
10-Q · Filed November 5, 2026 · Our reading of the company's report
The latest report
The extracted 10-Q text does not include the current quarter’s income statement, balance sheet, or cash-flow statements, so revenue, margins, EPS, cash balances, debt, working capital, and free cash flow cannot be…
Read full summary
The extracted 10-Q text does not include the current quarter’s income statement, balance sheet, or cash-flow statements, so revenue, margins, EPS, cash balances, debt, working capital, and free cash flow cannot be quantified or compared with prior periods. Operationally, management highlighted positive LUCIDITY results, with all primary and secondary endpoints met, and positive HELIOS results in 12 participants, but the Company remains pre-commercial with an accumulated deficit of $881.6 million and no committed source of additional capital. Key forward risks include reliance on single-source API manufacturers, unresolved derivative litigation, and the loss of smaller-reporting-company status beginning January 1, 2027.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Positive Avexitide LUCIDITY Results
Management reported positive topline results from LUCIDITY in August 2026; the trial met its prespecified primary endpoint and all secondary endpoints. Avexitide was described as generally well-tolerated across all 6 completed PBH clinical trials.
-
Wolfram Syndrome Program Advances
The Company reported positive topline results from the Phase 2 HELIOS trial of AMX0035 in 12 adult participants with Wolfram syndrome.
-
Securities Class Action Resolved
The Shih securities class action was resolved through a Court-approved settlement of $6.5 million, with a significant portion funded by insurance proceeds; the case was dismissed with prejudice on September 10, 2026.
-
Liquidity Supports Planned Operations
Management stated that existing cash, cash equivalents, and marketable securities as of September 30, 2026 provide financial resources to support planned operations and advance pipeline priorities, including potential avexitide commercialization.
-
AMX0114 Trial Enrollment Progress
The Company completed cohort 1 of the AMX0114 Phase 1 LUMINA trial with 12 participants in September 2025 and cohort 2 with 12 participants in March 2026.
-
Disclosure Controls Remain Effective
Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of September 30, 2026, with no material changes to internal control over financial reporting during the quarter.
What to watch
-
Large Deficit and Funding Dependence
The Company had an accumulated deficit of $881.6 million as of September 30, 2026 and expects significant losses for the foreseeable future. It also states that it has no committed source of additional capital.
-
Single-Source Manufacturing Exposure
The Company relies on single manufacturers for each avexitide and AMX0035 API. One commercial-supply arrangement is only a preliminary agreement and requires a definitive agreement, creating supply, timing, and cost risk.
-
Upcoming Reporting-Cost Increase
The Company will no longer qualify as a smaller reporting company beginning January 1, 2027. It expects additional personnel, systems, professional fees, and internal-control requirements, increasing compliance costs and execution risk.
-
Product Liability Coverage May Be Limited
The Company’s product-liability insurance provides coverage of up to $10.0 million in the aggregate, which may not fully cover potential liabilities as avexitide or other candidates advance toward commercialization.
-
Derivative Litigation Still Pending
The Massachusetts and Delaware derivative litigation remains unresolved: the parties are negotiating a settlement, and a joint status report is due November 16, 2026 if plaintiffs have not sought preliminary approval by that date. The Company states that the potential impact cannot currently be estimated.
-
Dilution and Resale Overhang
As of October 26, 2026, 128,562,904 common shares were outstanding and may be resold immediately without restriction unless held by affiliates. Future sales or equity offerings could pressure the share price and dilute existing holders.
Management's outlook
The extracted 10-Q text does not provide quantitative revenue, EPS, cash runway, or operating guidance. Management states that existing cash, cash equivalents, and marketable securities as of September 30, 2026 are expected to support planned operations, including potential avexitide commercialization, but does not disclose a duration or dollar amount.
Earlier filings 4
10-K · March 3, 2026
Amylyx remains a clinical-stage biopharma focused on avexitide (GLP-1 receptor antagonist for PBH) and a neurodegeneration program (AMX0035, AMX0114). The company reports no meaningful product revenue (reported revenue…
10-Q · November 6, 2025
Amylyx reported Q3 2025 product revenue of $0 and GAAP net loss per share of $(0.37), an improvement vs. Q3 2024. Operating loss narrowed to $(36,027) (in thousands) driven by lower operating expenses and a $256.7…
10-Q · August 7, 2025
Amylyx reported Q2 2025 GAAP net loss of $41,443 (per the condensed statements) with GAAP diluted EPS of $(0.46). Product revenue remained nil (Product revenue, net $—) while operating expenses declined to $42,857 from…
Smart money in AMLX
Totals from the last full session. Insider and politician figures cover 90 days.
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.
See every AMLX trade live.
The free pages stop at the last full session. Trader shows every trade as it prints.
Start tracking No card needed.